Genexine’s DNA Vaccine Shows Promise As Combo Therapy In Cervical Cancer
Executive Summary
Genexine is poised to continue to focus on developing therapeutic DNA vaccine GX-188E as combination therapy, following Phase II interim results in advanced cervical cancer that show impressive clinical benefit over pembrolizumab monotherapy.
You may also be interested in...
Genexine Counting On Hyleukin-7’s Potential As Versatile I-O Booster
Genexine’s recent M&A activity and foreign partnerships underscore its strategy on pipeline innovative therapeutics and biobetters as well as preparations to secure future growth engines, the Korean firm's vice-president tells Scrip in an interview.
Korea's AriBio Progresses Phase III Program For Oral Alzheimer's Contender
South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.
Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.